TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Bruce E. Sands  ¹     Geert R. D'Haens  ²     David B. Clemow  ³     Peter Irving  ⁴     Jordan T. Johns  ⁴     Theresa Hunter Gibble  ⁴     Maria T. Abreu  ⁵     Scott Lee  ⁶     Tadakazu Hisamatsu  ⁷     Taku Kobayashi  ⁸     Marla C. Dubinsky  ⁹     Severine Vermeire  ¹⁰     Corey A Siegel  ¹¹     Laurent Peyrin-Biroulet  ¹²     Richard Moses  ¹²     Joe Milata  ¹²     Vipin Arora  ¹²     Remo Panaccione  ¹³     Axel Dignass  ^14    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² Amsterdam University Medical Centers, Amsterdam, Netherlands
³ Eli Lilly and Company, Indianapolis, United States
⁴ Guy's and St. Thomas’ Hospitals, London, United Kingdom
⁵ University of Miami, Miller School of Medicine, Coral Gables, United States
⁶ University of Washington Medical Center, Seattle, United States
⁷ Kyorin University School of Medicine, Tokyo, Japan
⁸ Kitasato University Kitasato Institute Hospital, Minato-ku, Japan
⁹ Mount Sinai Hospital, Mount Sinai, New York City, United States
¹⁰ University Hospital Leuven, Leuven, Belgium
¹¹ Dartmouth-Hitchcock Medical Center, Lebanon, United States
¹² Nancy University Hospital, Vandoeuvre-les-Nancy, France
¹³ University of Calgary, Calgary, Canada
¹⁴ Agaplesion Markus Krankenhaus, Frankfurt/ Main, Germany

Topic
Endoscopy, IBD, Colorectal

Session
IL-23-Blockers in IBD: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)